Forced degradation (FD) studies play a critical role in pharmaceutical development and chemical manufacturing controls (CMC) by providing essential insight into degradation pathways, potential impurity formation, and analytical method performance. The understanding of these components directly impacts drug safety and the utility of analytical testing. Traditional approaches which rely on fixed limits for degradation and solution-phase stress testing often lack mechanistic justification and may generate non-representative or misleading outcomes.
In this white paper, Kishore Vatsavai, Principal Scientist, ARD, re-evaluates FD studies as a mechanistic, context driven tool that links molecular behavior with process, analytical, and regulatory strategy.
What you’ll learn in this white paper:
- Understand how forced degradation (FD) studies support degradation pathway identification, impurity profiling and control, manufacturing control, regulatory compliance and patient safety.
- Recognize the limitations of traditional FD approaches that rely on fixed degradation targets and solution-phase stress testing.
- Evaluate the influence of physical state and real-world conditions on degradation behavior and impurity profiles.
- Differentiate primary degradation pathways from secondary artifacts using kinetic and analytical tools.
Please fill out the form below to access the download
"*" indicates required fields
